Picture of Cannara Biotech logo

LOVE — Cannara Biotech News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousSmall CapSuper Stock

Cannara Biotech Q3 revenue tops estimates on expanded distribution

Cannara Biotech Q3 revenue tops estimates on expanded distribution


Overview

  • Canada cannabis producer's fiscal Q3 total revenues rose 16% yr/yr

  • Adjusted EBITDA for fiscal Q3 rose 11% yr/yr to C$8.5 mln

  • Company expanded distribution and increased cultivation capacity with two new grow zones


Outlook

  • Cannara expects to activate four more grow zones in fiscal 2027, raising capacity to 75,000 kg

  • Company anticipates launching Nugz Ampersand products, pending regulatory approvals and provincial listings

  • Cannara aims to maintain or grow retail market share and expand national distribution


Result Drivers

  • HIGHER SALES VOLUMES - Co said revenue and gross profit growth were driven by increased sales volumes and expanded production capacity following activation of new grow zones

  • PRODUCT INNOVATION - Deeper market penetration, product innovation and expanded product formats contributed to sales growth, per management

  • DISTRIBUTION EXPANSION - Co expanded national distribution and retail penetration, with products exceeding 49,000 points of distribution and increased share of retail listings


Company press release: ID:nGNX5W2vsM


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Total Revenues

Beat

C$31.80 mln

C$31.23 mln (3 Analysts)

Q3 EPS

C$0.05

Q3 Net Income

C$4.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Cannara Biotech

See all news